| Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin | Frank Vinluan | 11/18/19 | Boston |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| Dunsire, Forum Pharma Look Beyond Fidelity For Big Alzheimer’s Push | Ben Fidler | 04/22/15 | Boston |
| Pivoting From IPO, Syndax Inks Combo Trial Deal With Merck | Ben Fidler | 03/31/15 | Boston |
| Syndax CEO Says an Immuno-Oncology Thing Happened on the Way to IPO | Ben Fidler | 02/17/15 | Boston |
| Rodin Moves From Seedling to Neurology Startup With $12.9M Series A | Ben Fidler | 05/29/14 | Boston |
| Syndax Plots $69M IPO For Cancer Drug’s Stretch Run | Ben Fidler | 03/27/14 | Boston |
| East Coast Biotech Roundup: Enanta, NY Disruptors, Repligen, & More | Ben Fidler | 01/24/14 | Boston |
| Celgene Nabs Option to Buy Acetylon for More Than $1.7B | Ben Fidler | 07/29/13 | Boston |
| After Strikeout, San Diego’s MEI Pharma Looks to Rebuild Confidence | Bruce V. Bigelow | 12/17/12 | San Diego |
| San Diego Life Sciences Roundup: Regulus, MEI Pharma, Qualcomm & More | Bruce V. Bigelow | 08/16/12 | San Diego |
